IL13 and metabolic dysfunction-associated steatohepatitis: The pathway analysis indicated a temporal deregulation of type 2 immunity (IL-4, IL-13 axis) as well as IL-10, IL-18, and non-canonical NF- κβ signaling in NASH, where dysregulation of IL-18 and non-canonical NF-κβ signaling was specific for NASH patients (Figure 5E).